Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novavax, Inc.

Market Cap 1.5B 1.31B 1.21B 1.14B 2.13B 142B 2.14B 14.37B 5.57B 69.69B 5.64B 5.51B 242B P/E 2026 *
-19.3x
P/E 2027 * -35.9x
Enterprise Value 1.72B 1.5B 1.39B 1.3B 2.44B 162B 2.46B 16.47B 6.38B 79.86B 6.46B 6.32B 278B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 6.98x
Free-Float
93.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Operating Officer - 01/12/2020
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.5B
+1.44%+1.71%-10.98%-6.19% 43.13B
+3.31%+5.93%+310.97%+534.70% 34.65B
+2.84%+2.14%+9.34%+41.02% 30.03B
-1.70%-7.54%+8.43%-21.94% 28B
-1.90%-1.56%+10.24%+21.21% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+104.27% 13.14B
-0.57%-2.43%+5.08%+4.79% 12.53B
-0.26%+1.15%+98.13%+80.47% 12.25B
Average -0.86%+0.73%+60.00%+94.79% 23.61B
Weighted average by Cap. +0.68%+1.27%+65.47%+110.06%

Financials

2026 *2027 *
Net sales 410M 358M 331M 310M 581M 38.66B 585M 3.93B 1.52B 19.03B 1.54B 1.51B 66.17B 258M 225M 209M 196M 366M 24.38B 369M 2.47B 958M 12B 970M 949M 41.72B
Net income -79.31M -69.19M -64.04M -60.05M -112M -7.48B -113M -759M -294M -3.68B -298M -291M -12.8B -43.22M -37.71M -34.9M -32.73M -61.27M -4.08B -61.7M -414M -160M -2.01B -162M -159M -6.98B
Net Debt 219M 191M 177M 166M 310M 20.65B 313M 2.1B 812M 10.17B 822M 804M 35.35B 303M 265M 245M 230M 430M 28.6B 433M 2.9B 1.12B 14.07B 1.14B 1.11B 48.94B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!